Last reviewed · How we verify
T-817MA-H
T-817MA-H is a Small molecule drug developed by FUJIFILM Toyama Chemical Co., Ltd.. It is currently in Phase 2 development.
T-817MA-H is a small molecule being studied in a Phase 2 clinical trial for the treatment of Alzheimer's Disease. The trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of T-817MA-H in patients with mild to moderate Alzheimer's Disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | T-817MA-H |
|---|---|
| Sponsor | FUJIFILM Toyama Chemical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-817MA-H CI brief — competitive landscape report
- T-817MA-H updates RSS · CI watch RSS
- FUJIFILM Toyama Chemical Co., Ltd. portfolio CI
Frequently asked questions about T-817MA-H
What is T-817MA-H?
Who makes T-817MA-H?
What development phase is T-817MA-H in?
Related
- Manufacturer: FUJIFILM Toyama Chemical Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing